Wescott Financial Advisory Group LLC Reduces Stake in Johnson & Johnson $JNJ

Wescott Financial Advisory Group LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 19,219 shares of the company’s stock after selling 430 shares during the quarter. Wescott Financial Advisory Group LLC’s holdings in Johnson & Johnson were worth $3,187,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in JNJ. Nuveen LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $1,369,188,000. GAMMA Investing LLC increased its position in Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock valued at $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp increased its position in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC increased its position in Johnson & Johnson by 134.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock valued at $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp increased its position in Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $178.8990 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $180.61. The firm has a market capitalization of $430.85 billion, a P/E ratio of 19.13, a PEG ratio of 2.28 and a beta of 0.41. The business has a fifty day moving average of $163.04 and a 200 day moving average of $159.05.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on JNJ shares. Citigroup raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. Finally, Guggenheim reissued a “neutral” rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.